Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABLYF NASDAQ:BLUE NASDAQ:CBPO NASDAQ:ONCE NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/ABLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACBPOChina Biologic Products$119.99$119.23$99.74▼$120.05$4.72B0.47148,695 shs390,921 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/ARGENRepligen$122.83-1.3%$120.08$102.96▼$182.52$6.91B1.07777,704 shs162,411 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%BLUEbluebird bio0.00%0.00%0.00%0.00%-50.30%CBPOChina Biologic Products0.00%0.00%0.00%0.00%0.00%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%RGENRepligen+0.45%+4.29%+2.68%+0.24%-12.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/ABLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACBPOChina Biologic Products$119.99$119.23$99.74▼$120.05$4.72B0.47148,695 shs390,921 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/ARGENRepligen$122.83-1.3%$120.08$102.96▼$182.52$6.91B1.07777,704 shs162,411 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%BLUEbluebird bio0.00%0.00%0.00%0.00%-50.30%CBPOChina Biologic Products0.00%0.00%0.00%0.00%0.00%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%RGENRepligen+0.45%+4.29%+2.68%+0.24%-12.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABLYFAblynx 0.00N/AN/AN/ABLUEbluebird bio 2.17Hold$25.75418.11% UpsideCBPOChina Biologic Products 0.00N/AN/AN/AONCESpark Therapeutics 0.00N/AN/AN/ARGENRepligen 2.75Moderate Buy$168.7537.39% UpsideCurrent Analyst Ratings BreakdownLatest CBPO, ONCE, BLUE, RGEN, and ABLYF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$130.00 ➝ $155.009/12/2025RGENRepligenJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$145.00 ➝ $135.009/3/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$180.009/2/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$205.007/30/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$193.00 ➝ $204.007/30/2025RGENRepligenWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$180.00 ➝ $175.007/22/2025RGENRepligenStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOverweight$160.007/8/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetIn-Line$140.00 ➝ $130.00(Data available from 9/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABLYFAblynx$62.73M60.74N/AN/A$2.71 per share18.68BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CBPOChina Biologic Products$503.70M9.38$5.01 per share23.93$45.09 per share2.66ONCESpark Therapeutics$64.72M0.11N/AN/A$13.15 per share0.01RGENRepligen$634.44M10.89$3.08 per share39.90$35.21 per share3.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABLYFAblynx-$122.67MN/A0.00∞N/AN/AN/AN/AN/ABLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/ACBPOChina Biologic Products$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/AONCESpark Therapeutics-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/ARGENRepligen-$25.51M-$0.25N/A52.052.29-2.05%4.61%3.24%11/11/2025 (Estimated)Latest CBPO, ONCE, BLUE, RGEN, and ABLYF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025RGENRepligen$0.40$0.37-$0.03$0.26$174.62 million$182.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABLYFAblynxN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACBPOChina Biologic ProductsN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABLYFAblynxN/AN/AN/ABLUEbluebird bio0.370.510.33CBPOChina Biologic ProductsN/A12.0110.13ONCESpark Therapeutics0.354.674.35RGENRepligen0.268.597.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABLYFAblynxN/ABLUEbluebird bio87.43%CBPOChina Biologic Products34.77%ONCESpark Therapeutics88.37%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipABLYFAblynxN/ABLUEbluebird bio1.40%CBPOChina Biologic Products2.73%ONCESpark Therapeutics6.00%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABLYFAblynxN/A75.25 millionN/ANot OptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCBPOChina Biologic Products2,26939.36 millionN/AOptionableONCESpark Therapeutics36838.52 millionN/ANo DataRGENRepligen1,77856.26 million55.58 millionOptionableCBPO, ONCE, BLUE, RGEN, and ABLYF HeadlinesRecent News About These CompaniesRepligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript1 hour ago | seekingalpha.comRiverbridge Partners LLC Lowers Stock Position in Repligen Corporation $RGENSeptember 25 at 5:27 AM | marketbeat.com3 Reasons to Sell RGEN and 1 Stock to Buy InsteadSeptember 24 at 6:22 AM | msn.comDrug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN)September 23 at 8:18 PM | msn.comEvercore ISI Group Upgrades Repligen (RGEN)September 22 at 2:58 PM | msn.comRepligen Corporation (NASDAQ:RGEN) Receives $166.67 Consensus PT from AnalystsSeptember 22 at 2:43 AM | americanbankingnews.comRepligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 19, 2025 | marketbeat.comThree Stocks Estimated To Be Below Fair Value In September 2025September 17, 2025 | finance.yahoo.comKrilogy Financial LLC Invests $2.51 Million in Repligen Corporation $RGENSeptember 17, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Raises Position in Repligen Corporation $RGENSeptember 17, 2025 | marketbeat.comRepligen (RGEN) Stock Is Up, What You Need To KnowSeptember 16, 2025 | finance.yahoo.comStrs Ohio Buys Shares of 47,700 Repligen Corporation $RGENSeptember 16, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for Repligen Q4 Earnings?September 16, 2025 | marketbeat.comQ4 Earnings Estimate for Repligen Issued By Leerink PartnrsSeptember 16, 2025 | americanbankingnews.comWoodline Partners LP Buys New Shares in Repligen Corporation $RGENSeptember 15, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Given New $135.00 Price Target at Jefferies Financial GroupSeptember 14, 2025 | marketbeat.comOsterweis Capital Management Inc. Has $9.26 Million Position in Repligen Corporation $RGENSeptember 14, 2025 | marketbeat.comJefferies Financial Group Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock PriceSeptember 14, 2025 | americanbankingnews.comUnited Services Automobile Association Acquires New Shares in Repligen Corporation $RGENSeptember 13, 2025 | marketbeat.comWhy Repligen (RGEN) Stock Is Down TodaySeptember 12, 2025 | msn.comIs There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 29% Undervaluation?September 10, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 20253 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Alphabet’s Resurgence: It's Now a Clear Market LeaderBy Ryan Hasson | September 2, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025CBPO, ONCE, BLUE, RGEN, and ABLYF Company DescriptionsAblynx OTCMKTS:ABLYF$50.63 0.00 (0.00%) As of 04/30/2019Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.China Biologic Products NASDAQ:CBPOChina Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.Spark Therapeutics NASDAQ:ONCESpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Repligen NASDAQ:RGEN$122.83 -1.68 (-1.35%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NuScale Power: The SMR Stock at the Heart of the AI Energy Boom Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall Street Why Traders Are Doubling Down on SoundHound Stock After Big Rally Spotify Could Surge Higher—Here’s the Hidden Earnings Signal Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
